4basebio PLC
4BB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £1,174 | £605 | £328 | £268 |
| % Growth | 94% | 84.5% | 22.4% | – |
| Cost of Goods Sold | £1,048 | £631 | £92 | £89 |
| Gross Profit | £126 | -£26 | £236 | £179 |
| % Margin | 10.7% | -4.3% | 72% | 66.8% |
| R&D Expenses | -£106 | £0 | £2,385 | £1,961 |
| G&A Expenses | £0 | £11,668 | £2,198 | £1,647 |
| SG&A Expenses | £8,463 | £10,830 | £2,240 | £1,624 |
| Sales & Mktg Exp. | £0 | -£65 | £418 | £156 |
| Other Operating Expenses | £0 | £0 | £1,410 | £882 |
| Operating Expenses | £8,357 | £10,830 | £6,035 | £4,467 |
| Operating Income | -£8,231 | -£10,856 | -£5,799 | -£4,766 |
| % Margin | -701.1% | -1,794.4% | -1,768% | -1,778.4% |
| Other Income/Exp. Net | £9 | £4,344 | -£343 | £274 |
| Pre-Tax Income | -£8,222 | -£6,512 | -£6,142 | -£4,492 |
| Tax Expense | -£418 | £93 | -£414 | -£382 |
| Net Income | -£7,804 | -£6,605 | -£5,728 | -£4,110 |
| % Margin | -664.7% | -1,091.7% | -1,746.3% | -1,533.6% |
| EPS | -0.5 | -0.51 | -0.45 | -0.33 |
| % Growth | 2% | -13.3% | -36.4% | – |
| EPS Diluted | -0.5 | -0.51 | -0.45 | -0.33 |
| Weighted Avg Shares Out | 15,488 | 12,913 | 12,709 | 12,320 |
| Weighted Avg Shares Out Dil | 15,488 | 12,913 | 12,709 | 12,320 |
| Supplemental Information | – | – | – | – |
| Interest Income | £532 | £140 | £0 | £0 |
| Interest Expense | £416 | £409 | £343 | £204 |
| Depreciation & Amortization | £575 | £420 | £331 | £300 |
| EBITDA | -£7,231 | -£7,952 | -£5,468 | -£4,102 |
| % Margin | -615.9% | -1,314.4% | -1,667.1% | -1,530.6% |